{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-018892","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2022-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.463695+00:00","generated_at":"2026-06-25T22:19:11.271062+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Syndax Q1 2022 net loss $37.2M; cash $397.9M; clinical milestones on track for 2023","bullets":["Net loss $37.2M ($0.63/sh) vs $27.7M ($0.54) in Q1 2021; R&D spend $30.0M vs $21.9M.","Cash, cash equivalents and short-term investments $397.9M; 59M shares and equivalents outstanding.","FY2022 guidance: R&D $130-140M, total opex $160-170M; Q2 opex $38-42M.","Revumenib: AUGMENT-101 enrollment completion expected later 2022; topline data 1H23; combination trials underway.","Axatilimab: FDA Fast Track for cGVHD; AGAVE-201 topline data 1H23; potential BLA filing 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-018892","json":"https://secwatch.observer/filing/0001564590-22-018892.json","markdown":"https://secwatch.observer/filing/0001564590-22-018892.md","text":"https://secwatch.observer/filing/0001564590-22-018892.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000156459022018892/0001564590-22-018892-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000156459022018892/sndx-8k_20220509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T22:19:11.271062+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}